Skip to main content

Table 1 Expression levels of six potential biomarkers in patients with high-risk prostate cancer who underwent radical prostatectomy with and without neoadjuvant treatment

From: Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer

    

NNA

NHT

CHT

p-value

p value (NNA vs. CHT)

p value (NHT vs. CHT)

AR

Epithelial cells

Nuclear

Area

3.01 ± 0.10

2.06 ± 0.13

2.07 ± 0.0.06

< 0.001

< 0.001

0.984

  

Intensity

2.27 ± 0.08

1.94 ± 0.12

1.79 ± 0.05

< 0.001

< 0.001

0.208

  

Immunoreactivity score

7.20 ± 0.39

4.50 ± 0.40

4.16 ± 0.18

< 0.001

< 0.001

0.441

 

Cytoplasmic

Potitive/Negative (% of positive)

60/22 (73.2%)

48/16 (75.0%)

82/162 (33.6%)

< 0.001

< 0.001

< 0.001

Stromal cells

 

Area

1.21 ± 0.65

1.72 ± 0.81

1.55 ± 0.64

< 0.001

< 0.001

0.077

  

Intensity

1.08 ± 0.06

1.50 ± 0.08

1.33 ± 0.04

< 0.001

< 0.001

0.034

  

Immunoreactivity score

1.54 ± 0.14

2.94 ± 0.24

2.26 ± 0.10

< 0.001

< 0.001

0.010

GR

Epithelial cells

Nuclear

Area

1.80 ± 0.10

1.69 ± 0.13

2.36 ± 0.05

< 0.001

< 0.001

< 0.001

  

Intensity

1.55 ± 0.10

1.66 ± 0.12

1.88 ± 0.06

0.009

0.004

0.076

  

Immunoreactivity score

3.35 ± 0.29

3.38 ± 0.37

4.83 ± 0.20

< 0.001

< 0.001

0.001

 

Cytoplasmic

Potitive/Negative (% of positive)

0/80 (0%)

0/64 (0%)

38/196 (16.2%)

< 0.001

< 0.001

0.001

Stromal cells

 

Area

1.92 ± 0.07

1.78 ± 0.06

1.77 ± 0.05

0.180

0.055

0.875

  

Intensity

2.82 ± 0.02

2.88 ± 0.04

2.92 ± 0.03

0.133

0.049

0.396

  

Immunoreactivity score

5.41 ± 0.20

5.13 ± 0.19

5.23 ± 0.14

0.663

0.452

0.672

ERα

Stromal cells

Nuclear

Area

0.73 ± 0.08

1.13 ± 0.11

1.24 ± 007

< 0.001

< 0.001

0.392

  

Intensity

0.65 ± 0.07

1.19 ± 0.12

1.32 ± 0.07

< 0.001

< 0.001

0.391

  

Immunoreactivity score

0.85 ± 0.11

1.97 ± 0.25

2.51 ± 0.17

< 0.001

< 0.001

0.074

PR

Epithelial cells

Cytoplasmic

Area

0.82 ± 0.08

0.28 ± 0.07

0.30 ± 0.04

< 0.001

< 0.001

0.808

  

Intensity

1.54 ± 0.14

0.38 ± 0.09

0.52 ± 0.06

< 0.001

< 0.001

0.197

  

Immunoreactivity score

1.82 ± 0.20

0.50 ± 0.14

0.63 ± 0.08

< 0.001

< 0.001

0.455

Stromal cells

Nuclear

Area

1.13 ± 0.06

1.56 ± 0.09

2.30 ± 0.04

< 0.001

< 0.001

< 0.001

  

Intensity

2.24 ± 0.11

2.47 ± 0.09

2.94 ± 0.02

< 0.001

< 0.001

< 0.001

  

Immunoreactivity score

2.85 ± 0.19

3.75 ± 0.24

6.76 ± 0.14

< 0.001

< 0.001

< 0.001

MOB4A

Epithelial cells

Cytoplasmic

Area

2.21 ± 0.13

2.06 ± 0.15

2.63 ± 0.05

< 0.001

0.002

0.001

  

Intensity

1.09 ± 0.08

1.20 ± 0.11

1.49 ± 0.04

< 0.001

< 0.001

0.014

  

Immunoreactivity score

2.93 ± 0.24

3.20 ± 0.31

4.09 ± 0.13

< 0.001

< 0.001

0.004

YAP1

Epithelial cells

Nuclear

Area

1.54 ± 0.09

1.27 ± 0.15

1.76 ± 0.06

< 0.001

0.048

0.002

  

Intensity

1.68 ± 0.11

1.27 ± 0.15

1.78 ± 0.05

< 0.001

0.377

0.002

  

Immunoreactivity score

3.03 ± 0.24

2.83 ± 0.42

3.55 ± 0.17

0.086

0.104

0.113

 

Cytoplasmic

Area

1.95 ± 0.12

1.73 ± 0.14

2.42 ± 0.06

< 0.001

< 0.001

< 0.001

  

Intensity

1.14 ± 0.05

1.23 ± 0.08

1.73 ± 0.11

< 0.001

< 0.001

< 0.001

  

Immunoreactivity score

2.57 ± 0.26

2.90 ± 0.32

4.71 ± 0.20

< 0.001

< 0.001

< 0.001

  1. NNA no neoadjuvant threatment, NHT neoadjuvant hormonal therapy, CHT neoadjuvant chemohormonal therapy, AR androgen receptor, GR glucocorticoid receptor, ER estrogen receptor, PR progesterone receptor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us